{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:00:41Z","timestamp":1789898441301,"version":"4.0.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.dmpk.2026.101549","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:06:07Z","timestamp":1784246767000},"page":"101549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Population pharmacokinetic analysis and exposure\u2013response analysis of brexpiprazole in Japanese patients with agitation in Alzheimer's dementia"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1103-6837","authenticated-orcid":false,"given":"Koushi","family":"Higashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0619-7057","authenticated-orcid":false,"given":"Tomohiro","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikari","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6723-2937","authenticated-orcid":false,"given":"Yosuke","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5972-3711","authenticated-orcid":false,"given":"Stefanie","family":"Hennig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6704-6966","authenticated-orcid":false,"given":"Koichi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-0432","authenticated-orcid":false,"given":"Masami","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1858-1150","authenticated-orcid":false,"given":"Kaneyoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.dmpk.2026.101549_bib1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/gps.5030","article-title":"Using electronic health records to estimate the prevalence of agitation in Alzheimer disease\/dementia","volume":"34","author":"Halpern","year":"2019","journal-title":"Int J Geriatr Psychiatr"},{"issue":"4","key":"10.1016\/j.dmpk.2026.101549_bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1017\/S1041610222001041","article-title":"Agitation in cognitive disorders: progress in the International Psychogeriatric Association consensus clinical and research definition","volume":"36","author":"Sano","year":"2024","journal-title":"Int Psychogeriatr"},{"issue":"12","key":"10.1016\/j.dmpk.2026.101549_bib3","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1001\/archneur.64.12.1755","article-title":"Disruptive behavior as a predictor in Alzheimer disease","volume":"64","author":"Scarmeas","year":"2007","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.dmpk.2026.101549_bib4","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1176\/appi.ajp.2014.14040480","article-title":"Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the Cache County Dementia Progression Study","volume":"172","author":"Peters","year":"2015","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101549_bib5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J Pharmacol Exp Therapeut"},{"issue":"4","key":"10.1016\/j.dmpk.2026.101549_bib6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","article-title":"Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia: two 12-week, randomized, double-blind, placebo-controlled trials","volume":"28","author":"Grossberg","year":"2020","journal-title":"Am J Geriatr Psychiatr"},{"issue":"12","key":"10.1016\/j.dmpk.2026.101549_bib9","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jamaneurol.2023.3810","article-title":"Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial","volume":"80","author":"Lee","year":"2023","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.dmpk.2026.101549_bib11","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1002\/alz.14282","article-title":"Brexpiprazole treatment for agitation in Alzheimer's dementia: a randomized study","volume":"20","author":"Nakamura","year":"2024","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.dmpk.2026.101549_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2025.101057","article-title":"Population pharmacokinetics of brexpiprazole in Japanese healthy subjects and patients with schizophrenia","volume":"62","author":"Higashi","year":"2025","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101549_bib14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jcph.979","article-title":"Pharmacokinetics and safety of brexpiprazole following multiple-dose administration to Japanese patients with schizophrenia","volume":"58","author":"Ishigooka","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.dmpk.2026.101549_bib15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/pcn.12682","article-title":"Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: a 6-week, randomized, double-blind, placebo-controlled study","volume":"72","author":"Ishigooka","year":"2018","journal-title":"Psychiatr Clin Neurosci"},{"key":"10.1016\/j.dmpk.2026.101549_bib17","author":"Karlsson"},{"issue":"2","key":"10.1016\/j.dmpk.2026.101549_bib18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"issue":"2","key":"10.1016\/j.dmpk.2026.101549_bib19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","article-title":"Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R","volume":"90","author":"Comets","year":"2008","journal-title":"Comput Methods Progr Biomed"},{"issue":"2","key":"10.1016\/j.dmpk.2026.101549_bib20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/psp4.12161","article-title":"Model evaluation of continuous data pharmacometric models: metrics and graphics","volume":"6","author":"Nguyen","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101549_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","article-title":"Diagnosing model diagnostics","volume":"82","author":"Karlsson","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2026.101549_bib22","article-title":"Guidance for industry: pharmacokinetics in patients with impaired renal function \u2013 study design, data analysis, and impact on dosing and labeling","year":"2020","journal-title":"Draft Guidance"},{"key":"10.1016\/j.dmpk.2026.101549_bib25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2288-1-6","article-title":"The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study","volume":"1","author":"Vickers","year":"2001","journal-title":"BMC Med Res Methodol"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436726000352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436726000352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T09:15:14Z","timestamp":1789895714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436726000352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":18,"alternative-id":["S1347436726000352"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2026.101549","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetic analysis and exposure\u2013response analysis of brexpiprazole in Japanese patients with agitation in Alzheimer's dementia","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2026.101549","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101549"}}